KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D	sotorasib + VRx-510 Sensitive: D – Preclinical sotorasib + VRx-510 Sensitive : D
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	venetoclax + VRx-510 Sensitive: D – Preclinical venetoclax + VRx-510 Sensitive : D	venetoclax + VRx-510 Sensitive: D – Preclinical venetoclax + VRx-510 Sensitive : D
CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D
CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	CDKN2A deletion	Estrogen Receptor Positive Breast Cancer	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D
PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D
PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	PIK3CA mutation	Estrogen Receptor Positive Breast Cancer	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D
PAK4 deletion	Estrogen Receptor Positive Breast Cancer	PAK4 deletion	Estrogen Receptor Positive Breast Cancer	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D	ribociclib + VRx-510 Sensitive: D – Preclinical ribociclib + VRx-510 Sensitive : D
PAK4 deletion	Estrogen Receptor Positive Breast Cancer	PAK4 deletion	Estrogen Receptor Positive Breast Cancer	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D	palbociclib + VRx-510 Sensitive: D – Preclinical palbociclib + VRx-510 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	everolimus + dichloroacetate topical Sensitive: D – Preclinical everolimus + dichloroacetate topical Sensitive : D	everolimus + dichloroacetate topical Sensitive: D – Preclinical everolimus + dichloroacetate topical Sensitive : D
EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	EGFR L858R + EGFR T790M	Non Small Cell Lung Cancer	osimertinib + BX795 Sensitive: D – Preclinical osimertinib + BX795 Sensitive : D	osimertinib + BX795 Sensitive: D – Preclinical osimertinib + BX795 Sensitive : D

PDK1 inhibitor

PDK1 inhibitor

Associations(11)

Associations
(11)